Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | GRK2 | P25098 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787139 | 0.87 | — | — | |
| SCHEMBL22787136 | 0.86 | LMNA (0.36) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL29814134 | 0.86 | LMNA (0.36) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL22787158 | 0.86 | LMNA (0.36) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL24214414 | 0.85 | — | — | |
| SCHEMBL30231974 | 0.84 | SMN1; SMN2 (0.42) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL21098749 | 0.84 | SMN1; SMN2 (0.42) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL21052174 | 0.84 | SMN1; SMN2 (0.42) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL21098752 | 0.82 | SMN1; SMN2 (0.40) | LMNAGAAMAPTHTTROCK2 | |
| SCHEMBL21098751 | 0.80 | MAPT (0.40) | MAPTHTTROCK2GRK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-08-25 | — | — | US | disclosed |
| WO-2020248065-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | AADAC, ACSL3, ACSL1 | LMNA 845/4885GAA 1198/4885MAPT 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.